The complement Alternative Pathway is activated in hematological, renal, neurological, inflammatory, and ocular disorders. Our intellectual property addresses these diseases (rare and common). Our screening technology is capable of adding additional diseases to our existing portfolio. Our high affinity and high potency Antibody Therapies selectively block the Alternative Pathway without affecting the classical pathway which remains fully functional to control opsonization and bacterial clearance. These properties are essential to obtaining clearance on "Black Box Warning" label. In the disease state, numerous molecules of C3a, C3b, C5a, C5b and MAC are produced via dysregulation of the Alternative Pathway. Our lead drug candidates prevent the formation of these molecules to benefit in a variety of chronic rare and common diseases. Our laboratory model systems have proven that our clinical candidates have the potential to treat rare diseases.
With over 80 issued patents, NovelMed has established itself as a leader in rapid drug development, moving from concept to clinic in just three years. This accelerated progress is underpinned by a wealth of trade secrets and specialized know-how that safeguard and enhance our innovative processes. At the core of our success is our proprietary screening technology, which enables us to identify and develop highly selective and effective therapies with unmatched precision. This robust foundation not only strengthens our intellectual property portfolio but also positions us to deliver groundbreaking treatments to patients more efficiently, addressing critical needs in the medical community.
Our preclinical research has been strengthened by substantial funding from the National Institutes of Health (NIH), while our clinical programs have received support from a major pharmaceutical partner. The FDA has validated the quality of our clinical results, as demonstrated by the approval of Investigational New Drug (IND) applications for multiple indications and the Orphan Drug Designation of our lead antibodies. Two of our lead candidates have successfully completed Phase I trials in healthy volunteers. Several Phase II trials are listed on ClinicalTrials.gov, including an ongoing Phase II trial in patients with paroxysmal nocturnal hemoglobinuria (PNH). We continue to seek regulatory approvals for additional clinical indications in the orphan disease space.
NovelMed Therapeutics is a biotechnology company that conducts cutting-edge therapeutics research and development for complement-mediated diseases.
